sodium;(5Z,14Z)-N-(carboxymethyl)-20-hydroxyicosa-5,14-dienimidate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: sodium;(5Z,14Z)-N-(carboxymethyl)-20-hydroxyicosa-5,14-dienimidate
• 化学式: C22H38NNaO4
• 分子量: 403.5
• InChiKey: AKEILLLWYJQOJC-MJAXFGHUSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  0.42
• 重原子数：
  28
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  89.5
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Analogs of Peroxisome Proliferator Activated Receptor (PPAR) Agonists, and Methods of Using the Same
  申请人：THE UNIVERSITY OF TOLEDO

  公开号：US20160016920A1

  公开（公告）日：2016-01-21

  Analogs of PPAR5 and analogs of 20-OH-PGE2, which are PPAR5 agonists and 20-OH-PGE2 antagonists, respectively, and methods of using the same for inducing osteogenesis or chondrogenesis, are disclosed.

  本发明揭示了PPAR5类似物和20-OH-PGE2类似物，它们分别是PPAR5激动剂和20-OH-PGE2拮抗剂，并且揭示了使用它们诱导成骨或成软骨的方法。
• Proxisome proliferator activated receptor (PPAR) compounds and methods of using the same
  申请人：The University of Toledo

  公开号：US10351541B2

  公开（公告）日：2019-07-16

  Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.

  本研究公开了过氧化物酶体增殖物激活受体（PPAR）化合物，以及使用该化合物治疗骨折、治疗骨质疏松症和/或代谢性骨病、诱导骨生成和/或软骨生成的方法。
• Proxisome Proliferator Activated Receptor (PPAR) Compounds and Methods of Using the Same
  申请人：The University of Toledo

  公开号：US20170283385A1

  公开（公告）日：2017-10-05

  Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.
• PROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR) COMPOUNDS AND METHODS OF USING THE SAME
  申请人：The University of Toledo

  公开号：US20210163431A1

  公开（公告）日：2021-06-03

  Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.
• US9695137B2
  申请人：——

  公开号：US9695137B2

  公开（公告）日：2017-07-04